RAS Inhibitors Mark Therapeutic Revolution

Pancreatic cancer, one of the most aggressive and hard-to-treat cancers due to its early spread and late diagnosis, is seeing significant therapeutic advances at the Hospital Clínic in Barcelona. On World Pancreatic Cancer Day, 19th November 2026, specialists are highlighting new targeted treatments, including RAS inhibitors, which are showing promise in both metastatic and early-stage disease. Dr. Teresa Macarulla, head of the Medical Oncology Service at the Hospital Clínic [a major teaching hospital in Barcelona], described the new RAS inhibitors as a "therapeutic revolution". These drugs target the RAS signalling pathway, altered in around 90% of pancreatic ductal adenocarcinomas, which drives tumour growth. For decades, KRAS mutations were considered undruggable, but new agents like daraxonrasib are changing that. The Hospital Clínic is currently recruiting for the RASolute 304 trial, which evaluates daraxonrasib as an adjuvant treatment after surgery to reduce the risk of relapse. This builds on earlier results from a trial presented at the ASCO congress in June 2026, where the drug doubled survival in patients with metastatic disease receiving second-line treatment.

Until now we had hopeful data in metastatic cases. Now we must assess efficacy in earlier stages, and at the Clínic, we already have the trial underway.

Second Opinions Open New Surgical Possibilities

A second evaluation at a specialised centre can transform outcomes. Magdalena, a patient from Mallorca, travelled to the Hospital Clínic via the CSUR (Reference Centre, Service or Unit) pathway after being told her pancreatic tumour was inoperable. Following specialised assessment and preoperative treatment, her tumour became resectable. Dr. Elizabeth Pando, a surgeon in the Hepatopancreatobiliary Surgery and Transplantation Unit, stressed that a second opinion can reveal new treatment paths. The Hospital Clínic is accredited as a CSUR centre for borderline resectable pancreatic cancer, a status reflecting its high complexity surgical capabilities. By mid-October 2026, the hospital had performed 50 pancreatic resections, surpassing the total number for the whole of 2025. Between March and October 2026, its Multidisciplinary Committee evaluated 167 cases, ensuring tailored treatment plans.

Integrated Care Model Enhances Patient Support

Comprehensive care at the Clínic Barcelona Comprehensive Cancer Centre (4CB) involves close collaboration between oncology, surgery, nursing, psycho-oncology, and palliative care. The role of the specialised oncology nurse is central to coordinating this support and providing compassionate, continuous care. Despite progress, challenges remain. Research published in September 2026 by Dr. Macarulla and colleagues in Nature Medicine identified molecular mechanisms by which some tumours develop resistance to RAS inhibitors. Ongoing studies are exploring combination therapies to overcome this resistance and improve long-term outcomes. Patients across Spain are encouraged to seek referral to specialised centres like the Hospital Clínic to access clinical trials and advanced treatments. More information on eligibility and trials is available via the Hospital Clínic's official cancer research page.


Sources: Diari Catalunya, Escrito por: Ricard Ramos Izquierdo, clinicbarcelona.org, diaricatalunya.cat.